NIPPON ZOKI PHARMACEUTICAL
NIPPON ZOKI PHARMACEUTICAL
Industry:
Pharmaceutical
Founded:
1939-10-09
Address:
Osaka, Osaka, Japan
Country:
Japan
Website Url:
http://www.nippon-zoki.co.jp
Status:
Active
Contact:
(06)6203-0441
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager Google Universal Analytics Apache Global Site Tag Euro
Official Site Inspections
http://www.nippon-zoki.co.jp Semrush global rank: 296.63 K Semrush visits lastest month: 216.5 K
Unable to get host informations!!!
More informations about "Nippon Zoki Pharmaceutical"
About Us｜Nippon Zoki Pharmaceutical Co., Ltd. - 日本臓器製薬
The message from the president and CEO of Nippon Zoki Pharmaceutical can be found here, as well as corporate information including the organizational chart and affiliated companies. NZP …See details»
Nippon Zoki Pharmaceutical Co., Ltd. - 日本臓器製薬
Committed to fulfilling the unmet needs of patients and medical professionals, Nippon Zoki Pharmaceutical (NZP) transcends the conventional boundaries of a pharmaceutical company to deliver optimal medical care to society. Learn …See details»
組織図｜会社情報｜日本臓器製薬
日本臓器製薬の組織図についてご紹介します。 日本臓器製薬は人々の健康に貢献する製薬会社としてさらなる進化を目指していきます。See details»
日本臓器製薬 - Wikipedia
日本臓器製薬株式会社（にほんぞうきせいやく、英: Nippon Zoki Pharmaceutical Co., Ltd.）は、大阪府大阪市中央区平野町に本社を置く日本の製薬会社である。 See details»
NIPPON ZOKI PHARMACEUTICAL CO., LTD. | Member Companies
Address: 4-2-3 Hirano-machi, Chuo-ku, Osaka 541-0046. Contact: Phone：+81-6-6203-0441. FAX：+81-6-6203-4661. Homepage: http://www.nippon-zoki.co.jp/See details»
Chihiro Takenoshita - Phoenixi | フェニクシー
I’ve been in charge of healthtech new business development since 2017 after working in sales at Nippon Zoki Pharmaceutical Co., Ltd. Graduated from ICU, MBA from Keio University, and …See details»
Nippon Zoki Pharmaceutical - Crunchbase Company Profile
Oct 9, 2019 · Nippon Zoki Pharmaceutical is located in Osaka, Osaka, Japan. Who are Nippon Zoki Pharmaceutical 's competitors? Alternatives and possible competitors to Nippon Zoki …See details»
Nippon Zoki Pharmaceutical Co. Ltd. (Nippon Zoki Pharmaceutical …
了解Nippon Zoki Pharmaceutical Co. Ltd. (Nippon Zoki Pharmaceutical Co. Ltd.)公司的药物管线，治疗领域，技术平台，以及它的2项临床试验, 1篇新闻和82篇文献，疾病领域:神经系统疾 …See details»
NIPPON ZOKI PHARMACEUTICAL CO.,LTD. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for NIPPON ZOKI PHARMACEUTICAL CO.,LTD. of OSAKA, OSAKA. Get the latest business insights from Dun …See details»
Company Profile｜About Us｜Nippon Zoki Pharmaceutical Co., Ltd.
NZP's company profile can be found here. NZP is eager to make continuous progress as a pharmaceutical manufacturer dedicated to people's health the world over.See details»
JOMDD Announces Distribution Agreement to 40 countries｜サナ …
Feb 20, 2020 · SPACEVISION INC., Nippon Zoki Pharmaceutical Co., Ltd., and the Japanese Organization for Medical Device Development, Inc. (JOMDD) are proud to announce that we …See details»
Phase III study of bilayer sustained-release tramadol tablets in ...
Dec 29, 2023 · We investigated whether twice-daily administration of a bilayer tablet formulation of tramadol (35% immediate-release [IR] and 65% sustained-release) is as effective as four …See details»
Efficacy and Safety of Tramadol Hydrochloride Twice-Daily …
Nippon Zoki Pharmaceutical Co., Ltd. (Osaka, Japan) developed a twice-daily, bilayer formulation of sustained-release tramadol with an immediate-release component (65% sustained …See details»
医療用医薬品 : ジクロフェナクNa - KEGG
ニューキノロン系抗菌剤が脳内の抑制性神経伝達物質であるGABAの受容体結合を濃度依存的に阻害し、ある種の非ステロイド性抗炎症剤との共存下ではその阻害作用が増強されることが …See details»
Nippon Zoki to Develop Its 1st Biologic by Licensing Bone Forming ...
Oct 2, 2019 · Nippon Zoki Pharmaceutical has acquired exclusive development and marketing rights from the South Korean biotech CGBio for a bone morphogenetic protein 2 (BMP-2) …See details»
Efficacy and safety of twice‐daily tramadol hydrochloride bilayer ...
We investigated the efficacy and safety of twice-daily bilayer sustained-release tramadol hydrochloride tablets (35% immediate-release; 65% sustained-release) in patients with …See details»
Phase III study of bilayer sustained-release tramadol tablets in ...
Dec 29, 2023 · Purpose: We investigated whether twice-daily administration of a bilayer tablet formulation of tramadol (35% immediate-release [IR] and 65% sustained-release) is as …See details»
日本臓器製薬
日本臓器製薬の製品情報や、病気や治療に関する情報を掲載しています。 Work With Us 次代の医療ソリューションを追究し、新たな医療ビジネスのステージへと成長し続けていける仲間 …See details»
A Message from the President｜Nippon Zoki Pharmaceutical Co., …
The message from the president and CEO of Nippon Zoki Pharmaceutical can be found here, as well as corporate information including the organizational chart and affiliated companies. NZP …See details»
How Will the Unification Church Scandal Pan Out? | Nippon.com
18 hours ago · The October 2024 general election dealt a serious blow to the LDP-Kōmeitō ruling coalition. Suzuki Eito, a specialist in the dealings of the Korean Unification Church, examines …See details»